Selecta Biosciences Has Multiple Shots On Goal

  • The company offers its ImmTOR platform with its ability to decrease specific immune system responses which can improve the performance of multiple therapies.
  • We like these kinds of ‘multiple shots on goal’ situations and insiders seem to like it too, given the amount of insider buying.
  • On the other hand, while the company has cash to last them into Q2 2023, there are no guarantees for ultimate FDA approval and commercial development yet.
  • Learn More »